Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives
- PMID: 33655862
- DOI: 10.2174/1568026621666210303145430
Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives
Abstract
Breast cancer is the most frequent female cancer and one of the leading causes of cancer death in women. There are many chemotherapy agents available for the treatment of breast cancer. Still, the current therapeutic options have not fulfilled the desired outcomes, especially for drug-resistant breast cancer therapy. Thus, there is an urgent need to develop novel anti-breast cancer agents. Coumarin is ubiquitous in natural and synthetic bioactive compounds, and coumarin derivatives readily interact with a variety of enzymes and receptors in breast cancer cells. Moreover, the coumarin-based irosustat as the first-generation steroid sulfatase inhibitor in breast cancer is under clinical evaluation, revealing the potential of coumarin derivatives as novel anti-breast cancer agents. This review aims to describe the recent development of natural and synthetic coumarin derivatives with anti-breast cancer potential, covering the articles published from 2015 to 2020.
Keywords: Breast cancer; Cancer cells.; Coumarin; Dimers; Hybrids; Natural product; Steroid.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Coumarin derivatives with anticancer activities: An update.Arch Pharm (Weinheim). 2020 Aug;353(8):e2000025. doi: 10.1002/ardp.202000025. Epub 2020 May 8. Arch Pharm (Weinheim). 2020. PMID: 32383190 Review.
-
Coumarins as Potential Anti-drug Resistant Cancer Agents: A Mini Review.Curr Top Med Chem. 2021;21(19):1725-1736. doi: 10.2174/1568026620999201113110041. Curr Top Med Chem. 2021. PMID: 33185162 Review.
-
Current developments of coumarin-based anti-cancer agents in medicinal chemistry.Eur J Med Chem. 2015 Sep 18;102:611-30. doi: 10.1016/j.ejmech.2015.08.033. Epub 2015 Aug 17. Eur J Med Chem. 2015. PMID: 26318068 Review.
-
Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents.Anticancer Agents Med Chem. 2021;21(17):2351-2367. doi: 10.2174/1871520621666210129093857. Anticancer Agents Med Chem. 2021. PMID: 33511941
-
Design, Synthesis and Structure-Activity Relationship Studies of Glycosylated Derivatives of Marine Natural Product Lamellarin D.Eur J Med Chem. 2021 Mar 15;214:113226. doi: 10.1016/j.ejmech.2021.113226. Epub 2021 Jan 28. Eur J Med Chem. 2021. PMID: 33582387
Cited by
-
Coumarin as an Elite Scaffold in Anti-Breast Cancer Drug Development: Design Strategies, Mechanistic Insights, and Structure-Activity Relationships.Biomedicines. 2024 May 27;12(6):1192. doi: 10.3390/biomedicines12061192. Biomedicines. 2024. PMID: 38927399 Free PMC article. Review.
-
Triethylammonium Salts of Dicoumarol: Synthesis, Characterization, Human Antiglioblastoma, Antimicrobial and Antioxidant Studies.Cell Biochem Biophys. 2025 Mar;83(1):999-1008. doi: 10.1007/s12013-024-01532-1. Epub 2024 Sep 22. Cell Biochem Biophys. 2025. PMID: 39306823
-
Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy.Cell Commun Signal. 2024 Jul 15;22(1):361. doi: 10.1186/s12964-024-01733-4. Cell Commun Signal. 2024. PMID: 39010083 Free PMC article.
-
In-silico identification and exploration of small molecule coumarin-1,2,3-triazole hybrids as potential EGFR inhibitors for targeting lung cancer.Mol Divers. 2024 Dec;28(6):4301-4324. doi: 10.1007/s11030-024-10817-9. Epub 2024 Mar 12. Mol Divers. 2024. PMID: 38470555
-
Antiproliferative activity and toxicity evaluation of 1,2,3-triazole and 4-methyl coumarin hybrids in the MCF7 breast cancer cell line.RSC Med Chem. 2023 Mar 2;14(5):869-879. doi: 10.1039/d3md00031a. eCollection 2023 May 25. RSC Med Chem. 2023. PMID: 37252094 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources